APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibacterial (Drug) Resistance

Compare research editions
View pricing & licenses

Selected research

Industry Research

Antibacterial (Drug) Resistance Industry Research Report 2026

22 December 2025143 pages

Choose your research edition.

Industry ResearchAntibacterial (Drug) Resistance Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibacterial (Drug) Resistance Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Antibacterial (Drug) Resistance Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibacterial (Drug) Resistance Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibacterial (Drug) Resistance Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Antibacterial (Drug) Resistance market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Antibacterial (Drug) Resistance is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Antibacterial (Drug) Resistance is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Antibacterial (Drug) Resistance is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Antibacterial (Drug) Resistance include Merck, Pfizer, GSK, VenatoRx Pharmaceuticals, PENDOPHARM, Osel, Novexel, NanoSafe Coatings and Nabriva Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Antibacterial (Drug) Resistance market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Antibacterial (Drug) Resistance Market by Company

Merck

Pfizer

GSK

VenatoRx Pharmaceuticals

PENDOPHARM

Osel

Novexel

NanoSafe Coatings

Nabriva Therapeutics

Morphochem

Microbecide

Melinta Therapeutics

Lyndra

Isis Pharmaceuticals

InterMune

Evolva Holding

Demuris

ContraFect

Cerexa

Aventis Pharma

Austell Laboratories

Assembly Biosciences

Arpida

ANTABIO

Allergan

Acino Holdings

Achaogen

Absynth Biologics

Abbott Laboratories

AAIPharma Services

Antibacterial (Drug) Resistance Segment by Type

Ceftolozane-Tazobactam (Zerbaxa)

Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)

Ceftaroline Fosamil (Teflaro/ Zinforo)

Ceftazidime-Avibactam (Avycaz/ Zavicefta)

Telavancin (Vibativ)

Tedizolid Phosphate (Sivextro)

PHASE III DRUGS

Dalbavancin (Dalvance/ Xydalba)

Oritavancin (Orbactiv/ Nuvocid)

Fidaxomicin (Dificid / Dificlir)

Antibacterial (Drug) Resistance Segment by Application

Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)

Blood Stream Infections (BSI)

Community Acquired Bacterial Pneumonia (CABP)

Clostridium Difficile Infections (CDI)

Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Complicated Urinary Tract Infection (CUTI)

Complicated Intra-Abdominal Infections (CIAI)

Antibacterial (Drug) Resistance Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibacterial (Drug) Resistance market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibacterial (Drug) Resistance and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibacterial (Drug) Resistance.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Antibacterial (Drug) Resistance manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Antibacterial (Drug) Resistance by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Antibacterial (Drug) Resistance in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Antibacterial (Drug) Resistance Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Antibacterial (Drug) Resistance Sales (k units) of Manufacturers (2021-2026) Table 7. Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturers (2021-2026) Table 8. Global Antibacterial (Drug) Resistance Revenue of Manufacturers (2021-2026) Table 9. Global Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Antibacterial (Drug) Resistance Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Antibacterial (Drug) Resistance Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Antibacterial (Drug) Resistance, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Antibacterial (Drug) Resistance, Product Type & Application Table 14. Global Antibacterial (Drug) Resistance Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Antibacterial (Drug) Resistance by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Merck Company Information Table 19. Merck Business Overview Table 20. Merck Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Merck Antibacterial (Drug) Resistance Product Portfolio Table 22. Merck Recent Developments Table 23. Pfizer Company Information Table 24. Pfizer Business Overview Table 25. Pfizer Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Pfizer Antibacterial (Drug) Resistance Product Portfolio Table 27. Pfizer Recent Developments Table 28. GSK Company Information Table 29. GSK Business Overview Table 30. GSK Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. GSK Antibacterial (Drug) Resistance Product Portfolio Table 32. GSK Recent Developments Table 33. VenatoRx Pharmaceuticals Company Information Table 34. VenatoRx Pharmaceuticals Business Overview Table 35. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio Table 37. VenatoRx Pharmaceuticals Recent Developments Table 38. PENDOPHARM Company Information Table 39. PENDOPHARM Business Overview Table 40. PENDOPHARM Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio Table 42. PENDOPHARM Recent Developments Table 43. Osel Company Information Table 44. Osel Business Overview Table 45. Osel Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Osel Antibacterial (Drug) Resistance Product Portfolio Table 47. Osel Recent Developments Table 48. Novexel Company Information Table 49. Novexel Business Overview Table 50. Novexel Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Novexel Antibacterial (Drug) Resistance Product Portfolio Table 52. Novexel Recent Developments Table 53. NanoSafe Coatings Company Information Table 54. NanoSafe Coatings Business Overview Table 55. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio Table 57. NanoSafe Coatings Recent Developments Table 58. Nabriva Therapeutics Company Information Table 59. Nabriva Therapeutics Business Overview Table 60. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio Table 62. Nabriva Therapeutics Recent Developments Table 63. Morphochem Company Information Table 64. Morphochem Business Overview Table 65. Morphochem Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Morphochem Antibacterial (Drug) Resistance Product Portfolio Table 67. Morphochem Recent Developments Table 68. Microbecide Company Information Table 69. Microbecide Business Overview Table 70. Microbecide Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Microbecide Antibacterial (Drug) Resistance Product Portfolio Table 72. Microbecide Recent Developments Table 73. Melinta Therapeutics Company Information Table 74. Melinta Therapeutics Business Overview Table 75. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio Table 77. Melinta Therapeutics Recent Developments Table 78. Lyndra Company Information Table 79. Lyndra Business Overview Table 80. Lyndra Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Lyndra Antibacterial (Drug) Resistance Product Portfolio Table 82. Lyndra Recent Developments Table 83. Isis Pharmaceuticals Company Information Table 84. Isis Pharmaceuticals Business Overview Table 85. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio Table 87. Isis Pharmaceuticals Recent Developments Table 88. InterMune Company Information Table 89. InterMune Business Overview Table 90. InterMune Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. InterMune Antibacterial (Drug) Resistance Product Portfolio Table 92. InterMune Recent Developments Table 93. Evolva Holding Company Information Table 94. Evolva Holding Business Overview Table 95. Evolva Holding Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Evolva Holding Antibacterial (Drug) Resistance Product Portfolio Table 97. Evolva Holding Recent Developments Table 98. Demuris Company Information Table 99. Demuris Business Overview Table 100. Demuris Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Demuris Antibacterial (Drug) Resistance Product Portfolio Table 102. Demuris Recent Developments Table 103. ContraFect Company Information Table 104. ContraFect Business Overview Table 105. ContraFect Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. ContraFect Antibacterial (Drug) Resistance Product Portfolio Table 107. ContraFect Recent Developments Table 108. Cerexa Company Information Table 109. Cerexa Business Overview Table 110. Cerexa Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Cerexa Antibacterial (Drug) Resistance Product Portfolio Table 112. Cerexa Recent Developments Table 113. Aventis Pharma Company Information Table 114. Aventis Pharma Business Overview Table 115. Aventis Pharma Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio Table 117. Aventis Pharma Recent Developments Table 118. Austell Laboratories Company Information Table 119. Austell Laboratories Business Overview Table 120. Austell Laboratories Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio Table 122. Austell Laboratories Recent Developments Table 123. Assembly Biosciences Company Information Table 124. Assembly Biosciences Business Overview Table 125. Assembly Biosciences Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio Table 127. Assembly Biosciences Recent Developments Table 128. Arpida Company Information Table 129. Arpida Business Overview Table 130. Arpida Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Arpida Antibacterial (Drug) Resistance Product Portfolio Table 132. Arpida Recent Developments Table 133. ANTABIO Company Information Table 134. ANTABIO Business Overview Table 135. ANTABIO Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. ANTABIO Antibacterial (Drug) Resistance Product Portfolio Table 137. ANTABIO Recent Developments Table 138. Allergan Company Information Table 139. Allergan Business Overview Table 140. Allergan Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Allergan Antibacterial (Drug) Resistance Product Portfolio Table 142. Allergan Recent Developments Table 143. Acino Holdings Company Information Table 144. Acino Holdings Business Overview Table 145. Acino Holdings Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. Acino Holdings Antibacterial (Drug) Resistance Product Portfolio Table 147. Acino Holdings Recent Developments Table 148. Achaogen Company Information Table 149. Achaogen Business Overview Table 150. Achaogen Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 151. Achaogen Antibacterial (Drug) Resistance Product Portfolio Table 152. Achaogen Recent Developments Table 153. Absynth Biologics Company Information Table 154. Absynth Biologics Business Overview Table 155. Absynth Biologics Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 156. Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio Table 157. Absynth Biologics Recent Developments Table 158. Abbott Laboratories Company Information Table 159. Abbott Laboratories Business Overview Table 160. Abbott Laboratories Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 161. Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio Table 162. Abbott Laboratories Recent Developments Table 163. AAIPharma Services Company Information Table 164. AAIPharma Services Business Overview Table 165. AAIPharma Services Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 166. AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio Table 167. AAIPharma Services Recent Developments Table 168. Global Antibacterial (Drug) Resistance Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 169. Global Antibacterial (Drug) Resistance Sales by Region (2021-2026) & (k units) Table 170. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2021-2026) Table 171. Global Antibacterial (Drug) Resistance Sales by Region (2027-2032) & (k units) Table 172. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2027-2032) Table 173. Global Antibacterial (Drug) Resistance Revenue by Region (2021-2026) & (US$ Million) Table 174. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2021-2026) Table 175. Global Antibacterial (Drug) Resistance Revenue by Region (2027-2032) & (US$ Million) Table 176. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2027-2032) Table 177. North America Antibacterial (Drug) Resistance Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 178. North America Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 179. North America Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 180. North America Antibacterial (Drug) Resistance Revenue by Country (2021-2026) & (US$ Million) Table 181. North America Antibacterial (Drug) Resistance Revenue by Country (2027-2032) & (US$ Million) Table 182. Europe Antibacterial (Drug) Resistance Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 183. Europe Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 184. Europe Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 185. Europe Antibacterial (Drug) Resistance Revenue by Country (2021-2026) & (US$ Million) Table 186. Europe Antibacterial (Drug) Resistance Revenue by Country (2027-2032) & (US$ Million) Table 187. Asia Pacific Antibacterial (Drug) Resistance Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 188. Asia Pacific Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 189. Asia Pacific Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 190. Asia Pacific Antibacterial (Drug) Resistance Revenue by Country (2021-2026) & (US$ Million) Table 191. Asia Pacific Antibacterial (Drug) Resistance Revenue by Country (2027-2032) & (US$ Million) Table 192. South America Antibacterial (Drug) Resistance Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 193. South America Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 194. South America Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 195. South America Antibacterial (Drug) Resistance Revenue by Country (2021-2026) & (US$ Million) Table 196. South America Antibacterial (Drug) Resistance Revenue by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 198. Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 199. Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 200. Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2021-2026) & (US$ Million) Table 201. Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2027-2032) & (US$ Million) Table 202. Global Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 203. Global Antibacterial (Drug) Resistance Sales by Type (2027-2032) & (k units) Table 204. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2021-2026) Table 205. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2027-2032) Table 206. Global Antibacterial (Drug) Resistance Revenue by Type (2021-2026) & (US$ Million) Table 207. Global Antibacterial (Drug) Resistance Revenue by Type (2027-2032) & (US$ Million) Table 208. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2021-2026) Table 209. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2027-2032) Table 210. Global Antibacterial (Drug) Resistance Price by Type (2021-2026) & (US$/unit) Table 211. Global Antibacterial (Drug) Resistance Price by Type (2027-2032) & (US$/unit) Table 212. Global Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 213. Global Antibacterial (Drug) Resistance Sales by Application (2027-2032) & (k units) Table 214. Global Antibacterial (Drug) Resistance Sales Market Share by Application (2021-2026) Table 215. Global Antibacterial (Drug) Resistance Sales Market Share by Application (2027-2032) Table 216. Global Antibacterial (Drug) Resistance Revenue by Application (2021-2026) & (US$ Million) Table 217. Global Antibacterial (Drug) Resistance Revenue by Application (2027-2032) & (US$ Million) Table 218. Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2021-2026) Table 219. Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2027-2032) Table 220. Global Antibacterial (Drug) Resistance Price by Application (2021-2026) & (US$/unit) Table 221. Global Antibacterial (Drug) Resistance Price by Application (2027-2032) & (US$/unit) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. Antibacterial (Drug) Resistance Distributors List Table 225. Antibacterial (Drug) Resistance Customers List Table 226. Antibacterial (Drug) Resistance Industry Trends Table 227. Antibacterial (Drug) Resistance Industry Drivers Table 228. Antibacterial (Drug) Resistance Industry Restraints Table 229. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Antibacterial (Drug) Resistance Product Image Figure 5. Global Antibacterial (Drug) Resistance Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Antibacterial (Drug) Resistance Market Size (2021-2032) & (US$ Million) Figure 7. Global Antibacterial (Drug) Resistance Sales (2021-2032) & (k units) Figure 8. Global Antibacterial (Drug) Resistance Average Price (US$/unit) & (2021-2032) Figure 9. Ceftolozane-Tazobactam (Zerbaxa) Product Image Figure 10. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Product Image Figure 11. Ceftaroline Fosamil (Teflaro/ Zinforo) Product Image Figure 12. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Product Image Figure 13. Telavancin (Vibativ) Product Image Figure 14. Tedizolid Phosphate (Sivextro) Product Image Figure 15. PHASE III DRUGS Product Image Figure 16. Dalbavancin (Dalvance/ Xydalba) Product Image Figure 17. Oritavancin (Orbactiv/ Nuvocid) Product Image Figure 18. Fidaxomicin (Dificid / Dificlir) Product Image Figure 19. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) Product Image Figure 20. Blood Stream Infections (BSI) Product Image Figure 21. Community Acquired Bacterial Pneumonia (CABP) Product Image Figure 22. Clostridium Difficile Infections (CDI) Product Image Figure 23. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Product Image Figure 24. Complicated Urinary Tract Infection (CUTI) Product Image Figure 25. Complicated Intra-Abdominal Infections (CIAI) Product Image Figure 26. Global Antibacterial (Drug) Resistance Revenue Share by Manufacturers in 2025 Figure 27. Global Manufacturers of Antibacterial (Drug) Resistance, Manufacturing Sites & Headquarters Figure 28. Global Top 5 and 10 Antibacterial (Drug) Resistance Players Market Share by Revenue in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Antibacterial (Drug) Resistance Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 31. Global Antibacterial (Drug) Resistance Sales by Region in 2025 Figure 32. Global Antibacterial (Drug) Resistance Revenue by Region in 2025 Figure 33. North America Antibacterial (Drug) Resistance Market Size by Country in 2025 Figure 34. North America Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2032) Figure 35. North America Antibacterial (Drug) Resistance Revenue Market Share by Country (2021-2032) Figure 36. United States Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Europe Antibacterial (Drug) Resistance Market Size by Country in 2025 Figure 40. Europe Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2032) Figure 41. Europe Antibacterial (Drug) Resistance Revenue Market Share by Country (2021-2032) Figure 42. Germany Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. France Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. U.K. Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Italy Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Russia Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Spain Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Netherlands Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Switzerland Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Sweden Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Poland Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Asia Pacific Antibacterial (Drug) Resistance Market Size by Country in 2025 Figure 53. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2032) Figure 54. Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Country (2021-2032) Figure 55. China Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Japan Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. South Korea Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. India Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Australia Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Taiwan Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Southeast Asia Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Southeast Asia Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South America Antibacterial (Drug) Resistance Market Size by Country in 2025 Figure 64. South America Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2032) Figure 65. South America Antibacterial (Drug) Resistance Revenue Market Share by Country (2021-2032) Figure 66. Brazil Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Argentina Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Chile Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Middle East and Africa Antibacterial (Drug) Resistance Market Size by Country in 2025 Figure 70. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2032) Figure 71. Middle East and Africa Antibacterial (Drug) Resistance Revenue Market Share by Country (2021-2032) Figure 72. Egypt Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 73. South Africa Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 74. Israel Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 75. Türkiye Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 76. GCC Countries Antibacterial (Drug) Resistance Revenue Growth Rate (2021-2032) & (US$ Million) Figure 77. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2021-2032) Figure 78. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2021-2032) Figure 79. Global Antibacterial (Drug) Resistance Price (US$/unit) by Type (2021-2032) Figure 80. Global Antibacterial (Drug) Resistance Sales Market Share by Application (2021-2032) Figure 81. Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2021-2032) Figure 82. Global Antibacterial (Drug) Resistance Price (US$/unit) by Application (2021-2032) Figure 83. Antibacterial (Drug) Resistance Value Chain Figure 84. Antibacterial (Drug) Resistance Production Mode & Process Figure 85. Direct Comparison with Distribution Share Figure 86. Distributors Profiles Figure 87. Antibacterial (Drug) Resistance Industry Opportunities and Challenges

Scope & coverage.

Types
  • Ceftolozane-Tazobactam (Zerbaxa)
  • Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  • Ceftaroline Fosamil (Teflaro/ Zinforo)
  • Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  • Telavancin (Vibativ)
  • Tedizolid Phosphate (Sivextro)
  • PHASE III DRUGS
  • Dalbavancin (Dalvance/ Xydalba)
  • Oritavancin (Orbactiv/ Nuvocid)
  • Fidaxomicin (Dificid / Dificlir)
Applications
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • Blood Stream Infections (BSI)
  • Community Acquired Bacterial Pneumonia (CABP)
  • Clostridium Difficile Infections (CDI)
  • Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  • Complicated Urinary Tract Infection (CUTI)
  • Complicated Intra-Abdominal Infections (CIAI)
Companies covered
  • Merck
  • Pfizer
  • GSK
  • VenatoRx Pharmaceuticals
  • PENDOPHARM
  • Osel
  • Novexel
  • NanoSafe Coatings
  • Nabriva Therapeutics
  • Morphochem
  • Microbecide
  • Melinta Therapeutics
  • Lyndra
  • Isis Pharmaceuticals
  • InterMune
  • Evolva Holding
  • Demuris
  • ContraFect
  • Cerexa
  • Aventis Pharma
  • Austell Laboratories
  • Assembly Biosciences
  • Arpida
  • ANTABIO
  • Allergan
  • Acino Holdings
  • Achaogen
  • Absynth Biologics
  • Abbott Laboratories
  • AAIPharma Services

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Antibacterial (Drug) Resistance Market Size (2021-2032)
  4. 2.2.2 Global Antibacterial (Drug) Resistance Sales (2021-2032)
  5. 2.2.3 Global Antibacterial (Drug) Resistance Market Average Price (2021-2032)
  6. 2.3 Antibacterial (Drug) Resistance by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Ceftolozane-Tazobactam (Zerbaxa)
  9. 2.3.3 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  10. 2.3.4 Ceftaroline Fosamil (Teflaro/ Zinforo)
  11. 2.3.5 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  12. 2.3.6 Telavancin (Vibativ)
  13. 2.3.7 Tedizolid Phosphate (Sivextro)
  14. 2.3.8 PHASE III DRUGS
  15. 2.3.9 Dalbavancin (Dalvance/ Xydalba)
  16. 2.3.10 Oritavancin (Orbactiv/ Nuvocid)
  17. 2.3.11 Fidaxomicin (Dificid / Dificlir)
  18. 2.4 Antibacterial (Drug) Resistance by Application
  19. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  20. 2.4.2 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  21. 2.4.3 Blood Stream Infections (BSI)
  22. 2.4.4 Community Acquired Bacterial Pneumonia (CABP)
  23. 2.4.5 Clostridium Difficile Infections (CDI)
  24. 2.4.6 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  25. 2.4.7 Complicated Urinary Tract Infection (CUTI)
  26. 2.4.8 Complicated Intra-Abdominal Infections (CIAI)
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Antibacterial (Drug) Resistance Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Antibacterial (Drug) Resistance Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Antibacterial (Drug) Resistance Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Antibacterial (Drug) Resistance Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Antibacterial (Drug) Resistance Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Antibacterial (Drug) Resistance, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Antibacterial (Drug) Resistance, Product Type & Application
  8. 3.8 Global Manufacturers of Antibacterial (Drug) Resistance, Established Date
  9. 3.9 Global Antibacterial (Drug) Resistance Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Merck
  2. 4.1.1 Merck Company Information
  3. 4.1.2 Merck Business Overview
  4. 4.1.3 Merck Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Merck Antibacterial (Drug) Resistance Product Portfolio
  6. 4.1.5 Merck Recent Developments
  7. 4.2 Pfizer
  8. 4.2.1 Pfizer Company Information
  9. 4.2.2 Pfizer Business Overview
  10. 4.2.3 Pfizer Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Pfizer Antibacterial (Drug) Resistance Product Portfolio
  12. 4.2.5 Pfizer Recent Developments
  13. 4.3 GSK
  14. 4.3.1 GSK Company Information
  15. 4.3.2 GSK Business Overview
  16. 4.3.3 GSK Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 GSK Antibacterial (Drug) Resistance Product Portfolio
  18. 4.3.5 GSK Recent Developments
  19. 4.4 VenatoRx Pharmaceuticals
  20. 4.4.1 VenatoRx Pharmaceuticals Company Information
  21. 4.4.2 VenatoRx Pharmaceuticals Business Overview
  22. 4.4.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
  24. 4.4.5 VenatoRx Pharmaceuticals Recent Developments
  25. 4.5 PENDOPHARM
  26. 4.5.1 PENDOPHARM Company Information
  27. 4.5.2 PENDOPHARM Business Overview
  28. 4.5.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio
  30. 4.5.5 PENDOPHARM Recent Developments
  31. 4.6 Osel
  32. 4.6.1 Osel Company Information
  33. 4.6.2 Osel Business Overview
  34. 4.6.3 Osel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Osel Antibacterial (Drug) Resistance Product Portfolio
  36. 4.6.5 Osel Recent Developments
  37. 4.7 Novexel
  38. 4.7.1 Novexel Company Information
  39. 4.7.2 Novexel Business Overview
  40. 4.7.3 Novexel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Novexel Antibacterial (Drug) Resistance Product Portfolio
  42. 4.7.5 Novexel Recent Developments
  43. 4.8 NanoSafe Coatings
  44. 4.8.1 NanoSafe Coatings Company Information
  45. 4.8.2 NanoSafe Coatings Business Overview
  46. 4.8.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio
  48. 4.8.5 NanoSafe Coatings Recent Developments
  49. 4.9 Nabriva Therapeutics
  50. 4.9.1 Nabriva Therapeutics Company Information
  51. 4.9.2 Nabriva Therapeutics Business Overview
  52. 4.9.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio
  54. 4.9.5 Nabriva Therapeutics Recent Developments
  55. 4.10 Morphochem
  56. 4.10.1 Morphochem Company Information
  57. 4.10.2 Morphochem Business Overview
  58. 4.10.3 Morphochem Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Morphochem Antibacterial (Drug) Resistance Product Portfolio
  60. 4.10.5 Morphochem Recent Developments
  61. 4.11 Microbecide
  62. 4.11.1 Microbecide Company Information
  63. 4.11.2 Microbecide Business Overview
  64. 4.11.3 Microbecide Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Microbecide Antibacterial (Drug) Resistance Product Portfolio
  66. 4.11.5 Microbecide Recent Developments
  67. 4.12 Melinta Therapeutics
  68. 4.12.1 Melinta Therapeutics Company Information
  69. 4.12.2 Melinta Therapeutics Business Overview
  70. 4.12.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio
  72. 4.12.5 Melinta Therapeutics Recent Developments
  73. 4.13 Lyndra
  74. 4.13.1 Lyndra Company Information
  75. 4.13.2 Lyndra Business Overview
  76. 4.13.3 Lyndra Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Lyndra Antibacterial (Drug) Resistance Product Portfolio
  78. 4.13.5 Lyndra Recent Developments
  79. 4.14 Isis Pharmaceuticals
  80. 4.14.1 Isis Pharmaceuticals Company Information
  81. 4.14.2 Isis Pharmaceuticals Business Overview
  82. 4.14.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
  84. 4.14.5 Isis Pharmaceuticals Recent Developments
  85. 4.15 InterMune
  86. 4.15.1 InterMune Company Information
  87. 4.15.2 InterMune Business Overview
  88. 4.15.3 InterMune Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 InterMune Antibacterial (Drug) Resistance Product Portfolio
  90. 4.15.5 InterMune Recent Developments
  91. 4.16 Evolva Holding
  92. 4.16.1 Evolva Holding Company Information
  93. 4.16.2 Evolva Holding Business Overview
  94. 4.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Evolva Holding Antibacterial (Drug) Resistance Product Portfolio
  96. 4.16.5 Evolva Holding Recent Developments
  97. 4.17 Demuris
  98. 4.17.1 Demuris Company Information
  99. 4.17.2 Demuris Business Overview
  100. 4.17.3 Demuris Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Demuris Antibacterial (Drug) Resistance Product Portfolio
  102. 4.17.5 Demuris Recent Developments
  103. 4.18 ContraFect
  104. 4.18.1 ContraFect Company Information
  105. 4.18.2 ContraFect Business Overview
  106. 4.18.3 ContraFect Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 ContraFect Antibacterial (Drug) Resistance Product Portfolio
  108. 4.18.5 ContraFect Recent Developments
  109. 4.19 Cerexa
  110. 4.19.1 Cerexa Company Information
  111. 4.19.2 Cerexa Business Overview
  112. 4.19.3 Cerexa Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Cerexa Antibacterial (Drug) Resistance Product Portfolio
  114. 4.19.5 Cerexa Recent Developments
  115. 4.20 Aventis Pharma
  116. 4.20.1 Aventis Pharma Company Information
  117. 4.20.2 Aventis Pharma Business Overview
  118. 4.20.3 Aventis Pharma Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio
  120. 4.20.5 Aventis Pharma Recent Developments
  121. 4.21 Austell Laboratories
  122. 4.21.1 Austell Laboratories Company Information
  123. 4.21.2 Austell Laboratories Business Overview
  124. 4.21.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio
  126. 4.21.5 Austell Laboratories Recent Developments
  127. 4.22 Assembly Biosciences
  128. 4.22.1 Assembly Biosciences Company Information
  129. 4.22.2 Assembly Biosciences Business Overview
  130. 4.22.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio
  132. 4.22.5 Assembly Biosciences Recent Developments
  133. 4.23 Arpida
  134. 4.23.1 Arpida Company Information
  135. 4.23.2 Arpida Business Overview
  136. 4.23.3 Arpida Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Arpida Antibacterial (Drug) Resistance Product Portfolio
  138. 4.23.5 Arpida Recent Developments
  139. 4.24 ANTABIO
  140. 4.24.1 ANTABIO Company Information
  141. 4.24.2 ANTABIO Business Overview
  142. 4.24.3 ANTABIO Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 ANTABIO Antibacterial (Drug) Resistance Product Portfolio
  144. 4.24.5 ANTABIO Recent Developments
  145. 4.25 Allergan
  146. 4.25.1 Allergan Company Information
  147. 4.25.2 Allergan Business Overview
  148. 4.25.3 Allergan Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 Allergan Antibacterial (Drug) Resistance Product Portfolio
  150. 4.25.5 Allergan Recent Developments
  151. 4.26 Acino Holdings
  152. 4.26.1 Acino Holdings Company Information
  153. 4.26.2 Acino Holdings Business Overview
  154. 4.26.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  155. 4.26.4 Acino Holdings Antibacterial (Drug) Resistance Product Portfolio
  156. 4.26.5 Acino Holdings Recent Developments
  157. 4.27 Achaogen
  158. 4.27.1 Achaogen Company Information
  159. 4.27.2 Achaogen Business Overview
  160. 4.27.3 Achaogen Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  161. 4.27.4 Achaogen Antibacterial (Drug) Resistance Product Portfolio
  162. 4.27.5 Achaogen Recent Developments
  163. 4.28 Absynth Biologics
  164. 4.28.1 Absynth Biologics Company Information
  165. 4.28.2 Absynth Biologics Business Overview
  166. 4.28.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  167. 4.28.4 Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio
  168. 4.28.5 Absynth Biologics Recent Developments
  169. 4.29 Abbott Laboratories
  170. 4.29.1 Abbott Laboratories Company Information
  171. 4.29.2 Abbott Laboratories Business Overview
  172. 4.29.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  173. 4.29.4 Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio
  174. 4.29.5 Abbott Laboratories Recent Developments
  175. 4.30 AAIPharma Services
  176. 4.30.1 AAIPharma Services Company Information
  177. 4.30.2 AAIPharma Services Business Overview
  178. 4.30.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  179. 4.30.4 AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio
  180. 4.30.5 AAIPharma Services Recent Developments
5 Global Antibacterial (Drug) Resistance Market Scenario by Region
  1. 5.1 Global Antibacterial (Drug) Resistance Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Antibacterial (Drug) Resistance Sales by Region: 2021-2032
  3. 5.2.1 Global Antibacterial (Drug) Resistance Sales by Region: 2021-2026
  4. 5.2.2 Global Antibacterial (Drug) Resistance Sales by Region: 2027-2032
  5. 5.3 Global Antibacterial (Drug) Resistance Revenue by Region: 2021-2032
  6. 5.3.1 Global Antibacterial (Drug) Resistance Revenue by Region: 2021-2026
  7. 5.3.2 Global Antibacterial (Drug) Resistance Revenue by Region: 2027-2032
  8. 5.4 North America Antibacterial (Drug) Resistance Market Facts & Figures by Country
  9. 5.4.1 North America Antibacterial (Drug) Resistance Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Antibacterial (Drug) Resistance Sales by Country (2021-2032)
  11. 5.4.3 North America Antibacterial (Drug) Resistance Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Antibacterial (Drug) Resistance Market Facts & Figures by Country
  16. 5.5.1 Europe Antibacterial (Drug) Resistance Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Antibacterial (Drug) Resistance Sales by Country (2021-2032)
  18. 5.5.3 Europe Antibacterial (Drug) Resistance Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Antibacterial (Drug) Resistance Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Antibacterial (Drug) Resistance Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Antibacterial (Drug) Resistance Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Antibacterial (Drug) Resistance Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Antibacterial (Drug) Resistance Market Facts & Figures by Country
  41. 5.7.1 South America Antibacterial (Drug) Resistance Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Antibacterial (Drug) Resistance Sales by Country (2021-2032)
  43. 5.7.3 South America Antibacterial (Drug) Resistance Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Antibacterial (Drug) Resistance Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Antibacterial (Drug) Resistance Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Antibacterial (Drug) Resistance Sales by Type (2021-2032)
  2. 6.1.1 Global Antibacterial (Drug) Resistance Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Antibacterial (Drug) Resistance Sales Market Share by Type (2021-2032)
  4. 6.2 Global Antibacterial (Drug) Resistance Revenue by Type (2021-2032)
  5. 6.2.1 Global Antibacterial (Drug) Resistance Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Antibacterial (Drug) Resistance Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Antibacterial (Drug) Resistance Sales by Application (2021-2032)
  2. 7.1.1 Global Antibacterial (Drug) Resistance Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Antibacterial (Drug) Resistance Sales Market Share by Application (2021-2032)
  4. 7.2 Global Antibacterial (Drug) Resistance Revenue by Application (2021-2032)
  5. 7.2.1 Global Antibacterial (Drug) Resistance Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Antibacterial (Drug) Resistance Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Antibacterial (Drug) Resistance Value Chain Analysis
  2. 8.1.1 Antibacterial (Drug) Resistance Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Antibacterial (Drug) Resistance Production Mode & Process
  5. 8.2 Antibacterial (Drug) Resistance Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Antibacterial (Drug) Resistance Distributors
  8. 8.2.3 Antibacterial (Drug) Resistance Customers
9 Global Antibacterial (Drug) Resistance Analyzing Market Dynamics
  1. 9.1 Antibacterial (Drug) Resistance Industry Trends
  2. 9.2 Antibacterial (Drug) Resistance Industry Drivers
  3. 9.3 Antibacterial (Drug) Resistance Industry Opportunities and Challenges
  4. 9.4 Antibacterial (Drug) Resistance Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst